Shopping Cart
Remove All
Your shopping cart is currently empty
AZD-1305
Copy Product Info
😃Good
Catalog No. T30251Cas No. 872045-91-5
Alias UNII-CZO834LXQM, AZD 1305
AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias.
AZD-1305
Copy Product Info😃Good
Purity: 99.31%
Catalog No. T30251Alias UNII-CZO834LXQM, AZD 1305Cas No. 872045-91-5
AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $88 | In Stock | In Stock | |
| 5 mg | $223 | In Stock | In Stock | |
| 10 mg | $322 | In Stock | In Stock | |
| 25 mg | $496 | In Stock | In Stock | |
| 50 mg | $691 | In Stock | In Stock | |
| 100 mg | $945 | In Stock | In Stock | |
| 200 mg | $1,280 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $251 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.31%
Color:White to Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias. |
| Targets&IC50 | Inalate:4.3 microM, Inapeak:66 microM |
| In vitro | AZD1305 (0.1–30 µM, n = 6, each concentration applied for 3 min ; dog cardiomyocytes) concentration-dependently blocked INalate (IC50=4.3 microM) and INapeak (IC50=66 microM). In PFs, E-4031, but not AZD1305, markedly prolonged APD90 (from 380+/-15 to 597+/-86 ms, P<0.05) after the long CL and augmented APD90 instability (2+/-0.4 to 24+/-6.1 ms, P<0.05), increases significantly attenuated by AZD1305 and lidocaine.[3] |
| In vivo | AZD1305 ((36g/kg/min intravenously for 30 minutes ; anesthetized mongrel dogs) respectively increased QT and RR intervals from 290±7 to 397±15 ms (+37%, P<0.0001) and from 603±22 to 778±32 ms (+29%, P=0.002) at normal sinus rhythm. AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P<0.0001). AZD1305 slightly slowed the idioventricular rhythm.[2] |
| Synonyms | UNII-CZO834LXQM, AZD 1305 |
| Molecular Weight | 434.5 |
| Formula | C22H31FN4O4 |
| Cas No. | 872045-91-5 |
| Smiles | C(COC1=C(F)C=C(C#N)C=C1)N2CC3OC(CN(CCNC(OC(C)(C)C)=O)C3)C2 |
| Relative Density. | 1.24 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (57.54 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy AZD-1305 | purchase AZD-1305 | AZD-1305 cost | order AZD-1305 | AZD-1305 chemical structure | AZD-1305 in vivo | AZD-1305 in vitro | AZD-1305 formula | AZD-1305 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.